Respiratory Tract Drugs: Miscellaneous
TSURV1 “Survanta intratracheal susp. ”
Each ml contains phospholipids 25 mg, triglycerides 0.5-1.75 mg, free fatty acids 1.4-3.5 mg, protein 0.1-1 mg; 8 ml/vial.
適應症：預防和治療早產兒之呼吸窘迫症（Respiratory distress syndrome）。
Usual dose: Pediatric:
Respiratory distress syndrome in the newborn: intratracheally: first dose, 100 mg/kg (4 ml/kg); slowly inject one quarter of dose (> 2-3 sec) via catheter into endotracheal tube, remove catheter and manually ventilate at 60 breaths/min for 30 sec or until stable, reattach catheter and instill next 3 quarter doses using the same procedure; do not suction infant for 1 h after dosing unless significant airway obstruction occurs; during rescue strategy use mechanical ventilator rather than manual ventilation.
Adverse effect:
Serious: transient bradyarrhythmia, desaturation of blood; blocked endotracheal tube, reflux, endotracheal tube.
健保使用規範：(85/1/1)
1.新生兒hyaline membrane disease引起的呼吸窘迫症候群。
2.治療條件：患有hyaline membrane disease引起呼吸窘迫症候群的新生兒，須使用人工呼吸器，且FIＯ2設定於40%以上，仍無法維持blood gas PaO2大於80mmHg以上或Ｏ2 artery/Ｏ2 alveoli小於0.2，並排除其他原因，如肺炎所引起的呼吸窘迫情況。
3.使用時機：出生後48小時內最多使用4劑量，第一劑量建議在出生後 8小時內使用。